<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – August 27, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) reports today, that since January 1st, 2021, it has received proceeds of approximately CAD $8.2M as a result of the exercise of approximately 32.9 Million previously issued common share purchase warrants and broker warrants. As a result, over 94% of Innocan’s Warrants dated back to June 2020 and over 95% of…
...read full article on Newsfile Corp
